News Image

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

Provided By PR Newswire

Last update: Dec 26, 2024

USA News Group Commentary
Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, Dec. 26, 2024 /PRNewswire/ -- USA News Group News Commentary – Immunotherapy is transforming oncology by harnessing the immune system's power to fight cancer like never before. Notable advancements include a bioengineered therapeutic platform that boosts immune responses, providing targeted solutions for challenging cancer types. Researchers have also introduced an mRNA-based immunotherapy platform capable of selectively targeting cancer cells while preserving healthy tissue. These innovations underscore the relentless pursuit of breakthroughs in oncology to enhance patient outcomes. Among the key players driving recent progress in the field are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Erasca, Inc. (NASDAQ: ERAS), Allogene Therapeutics, Inc. (NASDAQ: ALLO), Context Therapeutics Inc. (NASDAQ: CNTX), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX).

Read more at prnewswire.com

ERASCA INC

NASDAQ:ERAS (2/21/2025, 8:16:00 PM)

After market: 1.41 0 (0%)

1.41

-0.05 (-3.42%)


ALLOGENE THERAPEUTICS INC

NASDAQ:ALLO (2/21/2025, 8:00:53 PM)

After market: 2.1692 0 (-0.04%)

2.17

-0.08 (-3.77%)


RECURSION PHARMACEUTICALS-A

NASDAQ:RXRX (2/21/2025, 8:00:01 PM)

After market: 9.27 -0.01 (-0.11%)

9.28

-1.07 (-10.34%)


CONTEXT THERAPEUTICS INC

NASDAQ:CNTX (2/21/2025, 8:10:27 PM)

After market: 0.7855 -0.03 (-3.5%)

0.814

+0.02 (+3.04%)


ONCOLYTICS BIOTECH INC

NASDAQ:ONCY (2/21/2025, 8:00:01 PM)

After market: 0.71 -0.02 (-2.15%)

0.7256

-0.01 (-1.79%)



Find more stocks in the Stock Screener

Follow ChartMill for more